Novartis enjoyed one of its best ever years of business performance in 2024, thanks to booming sales of its flagship product, the heart failure drug Entresto, in its final full year before generic competitors arrive.
Novartis Looks To Kisqali To Lead Growth, Calls On Trump To Fix The IRA
The Swiss firm enjoyed an exceptional 12% sales growth last year, and believes it can compensate for the imminent loss of blockbuster Entresto with new products. CEO Vas Narasimhan also laid out his three-point wish list for the new US administration.
More from Earnings
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.
More from Drug Pricing
• By
US President Trump’s threat of a “25% or higher” import tariff on pharmaceuticals sends ripples through an already uncertain environment. With about half of generics sourced from India, captains of industry read between the lines
• By
Mounjaro and Zepbound led Lilly’s 45% sales increase, but non-incretin products such as Verzenio and Taltz helped produce 20% growth outside of the incretin portfolio.
• By
Sun Pharma sees opportunities for Antibe’s otenaproxesul in the US and emerging markets and aims to get the clinical hold on the novel NSAID lifted. The firm is also focusing on its specialty business in Japan, amid pricing challenges for long-listed products.